Elite Pharmaceuticals Inc (ELTP)

[The ELTP King]

If Generic OxyContin doesn't launch next year, then reduce Elite's revenues by $10 million.

So $60 million instead of $70 million.

And the reason why I'm only reducing it by $10 million is because if Elite can launch Generic OxyContin next year, it will be during the second half of 2024 if not until Q4. Obviously, once we get things rolling, it will be a "needle mover" in 2025.

So here's the quarterly breakdown for CY2024, which will hopefully be Elite's new FY2024 when the new CFO gets hired.

Q1: $12 million
Q2: $14 million
Q3: $16 million
Q4: $18 million
Total: EXACTLY $60 million

Generic oxy will not launch next year even if approved. $70M has no realistic basis whatsoever.